Fig. 4: MYSM1 promotes LUAD tumor growth in vivo. | npj Precision Oncology

Fig. 4: MYSM1 promotes LUAD tumor growth in vivo.

From: MYSM1 promotes lung adenocarcinoma progression via TRAF2/3-mediated activation of MAPK and non-canonical NF-κB pathways

Fig. 4: MYSM1 promotes LUAD tumor growth in vivo.The alternative text for this image may have been generated using AI.

A Representative images of tumors in nude mice 25 days after subcutaneous injection of MYSM1 knockdown lung adenocarcinoma cells. The volume (B) and the weight (C) were lower for xenograft tumors with MYSM1 knockdown than for xenograft tumors with negative control. D Representative images of tumors in nude mice 25 days after subcutaneous injection of MYSM1 overexpression lung adenocarcinoma cells. The volume (E) and the weight (F) were higher for xenograft tumors with MYSM1 overexpression than for xenograft tumors with a negative control. G Representative images of HE staining and IHC staining of MYSM1, TRAF2, TRAF3 and Ki-67 in xenograft tumors. Scale bars: 50 μm. H Positive cell rate statistics of immunohistochemistry of tumor MYSM1, TRAF2, TRAF3, and Ki-67 in nude mice of different treatment groups. All data are presented as the mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

Back to article page